Market Overview:

The global macular degeneration treatment market reached a valuation of USD 9.9 billion in 2024 and is projected to attain USD 15.8 billion by 2033, reflecting a compound annual growth rate (CAGR) of 5.28% during 2025-2033. This growth is primarily driven by the increasing prevalence of age-related macular degeneration (AMD), particularly among the aging population, coupled with advancements in diagnostic technologies and treatment modalities. Additionally, rising awareness and early diagnosis initiatives are contributing significantly to market expansion.

Study Assumption Years:

• Base Year: 2024
• Historical Years: 2019-2024
• Forecast Years: 2025-2033

Macular Degeneration Treatment Market Key Takeaways:

• Market Size and Growth: The global macular degeneration treatment market was valued at USD 9.9 billion in 2024 and is anticipated to reach USD 15.8 billion by 2033, exhibiting a CAGR of 5.28% during the forecast period.

• Dominant Segment: Wet age-related macular degeneration (Wet AMD) dominated the global market, with intravitreal injections (IVT) being the primary treatment modality.

• Route of Administration: The intravitreal route is the most commonly utilized method for administering treatments, owing to its direct delivery to the affected area.

• End Users: Hospitals and ambulatory surgical centers are the primary end users, reflecting the critical role of specialized healthcare facilities in managing macular degeneration.

• Regional Insights: North America leads the market due to high healthcare spending and advanced medical infrastructure, followed by Europe, which shows substantial growth owing to increased research funding and an aging population.

Market Growth Factors:

There are tons of advancements made in technology.

Massive technological advancements have occurred in the treatment arena of macular diseases, particularly in diagnostics and treatment modalities. For example, with the development of optical coherence tomography (OCT) technologies, the methods are excellent for early detection and monitoring the disease's on-going period to timely and effective intervention. In addition, anti-VEGF therapies have provided a totally different impetus to the treatment methodology of wet AMD in obtaining improved visual outcome for patients with the condition. The facilitation of telemedicine and artificial intelligence (AI) is further making patient management and individualized treatment plans much easier and is, therefore, contributing to market growth.

Regulatory Influence:

Recognizing the increasing burden of macular degeneration, regulatory agencies across the globe are sparing no efforts in enabling the new treatments for macular degeneration to be approved and commercialized. Such channels of accelerated approval and orphan drug designation are also incentivizing the pharmaceutical companies to invest into research and development of such new treatments. The FDA has given priority review to several upcoming therapies concerning both kinds of AMD-wet and dry. Such regulatory support facilitates speedy availability of innovative therapies by creating a healthy competitive environment for the market to thrive.

Increasing Market Demand:

Market demand is further driven by the prevalent increase of macular degeneration, especially among the geriatric population. As life expectancy increases worldwide, the incidence of age-associated ocular conditions such as AMD is predicted to increase accordingly. Increased awareness about eye health and early diagnosis is causing an increase in screening and detection rates. More patients are proactive in seeking medical attention, thus increasing the adoption of treatments. This increased demand leads to investments from pharmaceutical and medical device companies in developing better and more affordable therapies.

Request Sample For PDF Report: https://www.imarcgroup.com/macular-degeneration-treatment-market/requestsample

Market Segmentation:

Breakup by Type:

• Dry Age-related Macular Degeneration
• Wet Age-related Macular Degeneration

Breakup by Stage of Disease:

• Early Stage
• Intermediate Stage
• Late Stage

Breakup by Route of Administration:

• Intravenous Route
• Intravitreal Route

Breakup by End User:

• Hospitals
• Ambulatory Surgical Center
• Others

Market Breakup by Region:

• North America (United States, Canada)
• Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
• Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
• Latin America (Brazil, Mexico, Others)
• Middle East and Africa

Regional Insights:

North America leads the macular degeneration treatment market, driven by high healthcare expenditure, advanced medical infrastructure, and a growing elderly population susceptible to age-related macular degeneration. The region's emphasis on early diagnosis and the adoption of innovative therapies further bolster its market dominance.

Recent Developments & News:

The macular degeneration treatment landscape has seen significant advancements with the approval of multiple aflibercept biosimilars. In May 2024, the U.S. FDA approved aflibercept-jbvf (Yesafili) and aflibercept-yszy (Opuviz), offering new therapeutic options. Subsequently, aflibercept-mrbb (Ahzantive) received approval in June 2024, followed by aflibercept-abzv (Enzeevu) and aflibercept-ayyh (Pavblu) in August 2024. These developments enhance treatment accessibility and may reduce costs. Additionally, the FDA's recent acceptance of Teva and Alvotech's AVTO6 for review positions it as a potential competitor to Regeneron's Eylea, reflecting a dynamic shift towards more affordable biosimilar treatments.

Key Players:

• Aerie Pharmaceuticals Inc.
• Bausch Health Companies Inc.
• Bayer AG
• F. Hoffmann-La Roche Ltd
• Iveric Bio Inc.
• Novartis AG
• Panoptica
• Pfizer Inc.
• Phio Pharmaceuticals
• Regeneron Pharmaceuticals Inc.
• Regenxbio Inc.
• Santen Pharmaceutical Co. Ltd.

Note: If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.